Industry analyst GlobalData has presented research into the growing market for GLP-1 therapies, noting the significance of Roche’s (ROG: SIX) recent acquisition in this area.
At the end of 2023, the company paid $2.7 billion to buy Carmot Therapeutics, a privately owned US company based in Berkeley, California.
As market leaders Novo Nordisk (NOV: N) and Eli Lilly (NYSE: LLY) break new ground in the treatment of obesity with innovative products expected to be worth tens of billions of dollars, there is strengthening interest in this therapeutic modality from a wide range of companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze